# Nortech Systems Inc: Form 10-Q for the period ended Sep 30, 2017

- Company: [Nortech Systems Inc](/companies/nsys.md) (CIK 722313)
- Form: 10-Q
- Filed: 2017-11-08
- Accepted by EDGAR: Nov 8, 2017, 16:16 ET
- Period: 2017-09-30
- Accession: 0001104659-17-066996
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/722313/000110465917066996/a17-20630_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/722313/000110465917066996/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2017-07-01 to 2017-09-30 | $24.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2017-01-01 to 2017-09-30 | $76.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2017-07-01 to 2017-09-30 | $3.5m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2017-01-01 to 2017-09-30 | $10.0m | us-gaap:GrossProfit |
| Operating income | 3 months, 2017-07-01 to 2017-09-30 | $284.4k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2017-01-01 to 2017-09-30 | $499.5k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-07-01 to 2017-09-30 | $171.7k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2017-01-01 to 2017-09-30 | $452.7k | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-07-01 to 2017-09-30 | $69.3k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2017-01-01 to 2017-09-30 | −$141.1k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-07-01 to 2017-09-30 | $43.4k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2017-01-01 to 2017-09-30 | $13.1k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-07-01 to 2017-09-30 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2017-01-01 to 2017-09-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-07-01 to 2017-09-30 | $0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2017-01-01 to 2017-09-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-07-01 to 2017-09-30 | 2,748,533 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2017-01-01 to 2017-09-30 | 2,748,973 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2017-01-01 to 2017-09-30 | $614.8k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2017-01-01 to 2017-09-30 | $573.7k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2017-01-01 to 2017-09-30 | $16.9k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2017-09-30 | $530.8k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-09-30 | $41.8m | us-gaap:AssetsCurrent |
| Total assets | at 2017-09-30 | $57.5m | us-gaap:Assets |
| Current liabilities | at 2017-09-30 | $20.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-09-30 | $35.2m | us-gaap:Liabilities |
| Long-term debt | at 2017-09-30 | $4.6m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2017-09-30 | $990.8k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2017-09-30 | $22.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 18,415 characters.

### Overview

We are a Maple Grove, Minnesota based full-service electronics manufacturing services (“EMS”) contract manufacturer of medical devices and systems wire and cable assemblies, printed circuit board assemblies and higher-level box builds for a wide range of industries. We provide value added engineering services and technical support including design, testing, prototyping and supply chain management to our customers in the medical, aerospace and defense and industrial equipment markets. We maintain facilities in Minnesota, US; Monterrey, Mexico; and Suzhou, China. All of our facilities are certified to one or more of the ISO/AS standards, including 9001, AS9100 and 13485, with most having additional certifications based on the needs of the customers they serve.

### 2017 Third Quarter Results

The third quarter of 2017 revenue was $28.3 million, compared to revenue of $29.7 million in the third quarter of 2016. Medical market revenue decreased $1.0 million or 7.4% from prior year with our defense revenue down by $0.2 million or 5.0% and industrial revenue down $0.2 million or 1.5%. Heading into the fourth quarter, our backlog at September 30, 2017 is down 7.5% from the start of the quarter and 15.2% compared to the prior year.

Our third quarter 2017 gross margin of $3.5 million or 12.4% of sales was down $0.3 million and 30 basis points from the prior year due to reduced sales volume.

Operating profit for the third quarter of 2017 was $0.3 million as compared to $0.2 million for the prior year’s third quarter. The $0.1 million increase was due to the continued focused effort on cost containment and expense reduction.

Net income for the three months ended September 30, 2017 was $43,371 or $0.02 profit per basic and diluted common share compared to net income for the three months ended September 30, 2016 of $0.1 million or $0.02 profit per basic and diluted common share. Net income for the nine months ended September 30, 2017 was $13,052 with no earnings per basic and diluted common share compared to net loss for the nine months ended September 30, 2016 of $0.1 million or $0.02 loss per basic and diluted common share.

### Results of Operations

The following table presents statements of operations data as percentages of total net sales for the periods indicated:

|  | Three Months Ended September 30, 2017 | 2016 | Nine Months Ended September 30, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| Net Sales | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of Goods Sold | 87.6 | 87.3 | 88.5 | 88.3 |
| Gross Profit | 12.4 | 12.7 | 11.5 | 11.7 |
| Selling Expenses | 4.0 | 3.8 | 4.2 | 4.3 |
| General and Administrative Expenses | 7.4 | 8.3 | 7.1 | 7.1 |
| Gain on Sale of Property and Equipment | 0.0 | 0.0 | (0.4) | 0.0 |
| Income from Operations | 1.0 | 0.6 | 0.6 | 0.3 |
| Other Expenses | (0.6) | (0.4) | (0.7) | (0.4) |
| Income (Loss) Before Income Taxes | 0.4 | 0.2 | (0.1) | (0.1) |
| Income Tax Expense (Benefit) | 0.2 | 0.0 | (0.2) | 0.0 |
| Net Income (Loss) | 0.2% | 0.2% | 0.1% | (0.1)% |

### Net Sales

Net sales by our major EMS industry markets for the three and nine month periods ended September 30, 2017 and 2016 were as follows:

|  | Three Months Ended September 30, | Nine Months Ended September 30, |
| --- | ---: | ---: |
|  | **2017** **2016%** | **2017** **2016%** |
| **(in thousands)** | **$$** **Change** | **$$** **Change** |
| Aerospace and Defense | 4,027 4,240 -5.0% | 11,264 12,427 -9.4% |
| Medical | 12,753 13,776 -7.4% | 41,009 38,058 7.8% |
| Industrial | 11,530 11,702 -1.5% | 34,489 37,129 -7.1% |
| Total Sales | 28,310 29,718 -4.7% | 86,762 87,614 -1.0% |

Net sales were $28.3 million in the third quarter of 2017, as compared to $29.7 million in the third quarter of the prior year, a decrease of $1.4 million or 4.7%. Net sales results were varied by markets. The medical market decreased by $1.0 million or 7.4% primarily due to medical device project delays and lack of funding for certain customers. The industrial market sector was slightly down $0.2 million in the third quarter of 2017 as compared to the same quarter of 2016, primarily from lower demand levels from our transportation equipment customers. Net sales from the aerospace and defense markets decreased by $0.2 million or 5.0% in the third quarter of 2017 as compared to the third quarter of 2016 due to customer mix. Programs frequently fluctuate in demand or come to an end and are replaced by new programs.

Net sales were $86.8 million for the nine months ended September 30, 2017, as compared to $87.6 million in the prior year, a decrease of $0.8 million or 1.0%. For the nine months ended September 30, 2017, medical sales increased by $3.0 million or 7.8%, industrial sales were down $2.6 million or 7.1%, primarily from lower demand levels from our transportation equipment customers and sales from the aerospace and defense markets decreased $1.2 million or 9.4% due to lower customer demands.

### Backlog

90-day backlog by our major EMS industry markets are as follows:

*(in thousands)*

|  | Backlog as of the Quarter Ended September 30, 2017 | June 30, 2017 | September 30, 2016 |
| --- | ---: | ---: | ---: |
| Aerospace and Defense | $4,524 | $4,252 | $3,565 |
| Medical | 7,897 | 10,762 | 12,282 |
| Industrial | 7,860 | 6,900 | 8,074 |
| Total Backlog | $20,281 | $21,914 | $23,921 |

Our 90-day order backlog as of September 30, 2017 was $20.3 million, a 7.5% decrease from the beginning of the quarter and a 15.2% decrease as compared to the prior year. Backlog for our medical customers has decreased 35.7% and 26.6% over the prior year and prior quarter, respectively due to recent demand adjustments by several customers that cited excess inventory levels accumulated over this year. The aerospace and defense backlog increased 6.4% since the beginning of the quarter, and increased 26.9% from the prior year. Our industrial customers’ backlog increased 13.9% since from the beginning of the quarter and decreased 2.6% from the prior year, strengthening our position heading into the fourth quarter. Our backlog consists of firm purchase orders and we expect a major portion of the current 90-day backlog to be realized as revenue during the following quarter.

Our 90-day backlog varies due to order size, manufacturing delays, contract terms and conditions and timing from customer delivery schedules and releases. These variables cause inconsistencies in comparing the backlog from one period to the next.

### Gross Profit

Gross profit as a percent of net sales for the three months ended September 30, 2017 and 2016, was 12.4% and 12.7%, respectively. The decrease in gross profit in the third quarter of 2017 as compared to the same period last year was primarily due to customer mix and under utilized plant capacity. Gross profit as a percentage of net sales for the nine months ended September 30, 2017 and 2016 was 11.5% and 11.7%, respectively.

### Selling Expense

Selling expense for the three months ended September 30, 2017 and 2016 was $1.1 million or 4.0% of sales and $1.1 million or 3.8% of sales, respectively. We will continue to fund business development to support activities and marketing initiatives to maintain existing business and stimulate sales growth. Selling expense for the nine months ended September 30, 2017 and 2016 was $3.7 million or 4.2% of sales and $3.7 million or 4.3% of sales, respectively.

### General and Administrative Expense

General and administrative expenses for the three months ended September 30, 2017 and 2016, were $2.1 million or 7.4% of sales and $2.5 million or 8.3% of sales, respectively. General and administrative expenses for the nine months ended September 30, 2017 and 2016 were $6.2 million or 7.1% of sales and $6.3 million or 7.1% of sales, respectively.

### Gain from Sale of Property and Equipment

Net gain from sale of property and equipment for the nine months ended September 30, 2017 was $0.4 million from the sale of the Augusta building and building improvements (see Note 6). There was no gain from sale of property and equipment recorded in 2016.

### Income from Operations

Third quarter 2017 income from operations was $0.3 million as compared to an income of $0.2 million for the third quarter in 2016. Income from operations for the first nine months in 2017 was $0.5 million as compared to $0.3 million for the same comparable period in 2016. A portion of the increase in income from operations for the nine-month period was due to bad debt recovery.

### Income Taxes

The differences between federal income taxes computed at the federal statutory rate and reported income taxes for the three months ended September 30, 2017 and 2016 are as follows:

|  | Three Months Ended September 30, 2017 | 2016 | Nine Months Ended September 30, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| Statutory federal tax provision benefit | $38,000 | $17,000 | $(43,000) | $(38,000) |
| State income tax expense (benefit) | 9,500 | 8,000 | 9,000 | 24,000 |
| Income tax credits | (25,000) | (20,000) | (75,000) | (60,000) |
| Change in uncertain tax positions | 2,500 | — | 7,500 | — |
| Return to provision true up | 74,000 | (22,000) | 74,000 | (22,000) |
| Foreign tax benefit | (42,500) | 44,000 | (124,500) | 44,000 |
| Other | 12,843 | (40,000) | 10,939 | (4,000) |
| Income tax benefit | $69,343 | $(13,000) | $(141,061) | $(56,000) |

The Company estimates the effective tax rate for the full fiscal year and records a quarterly income tax provision based on the anticipated rate and refines our estimates quarterly based on facts and circumstances including discrete events, by each jurisdiction. Our effective tax rate for the three and nine months ended September 30, 2017 was 61.5% and 110.2%, respectively. Our effective tax rate for the three and nine months ended September 30, 2016 was (25.8%) and 50.9%, respectively. The increase in our current year-to-date effective rate versus prior year is due mainly to the higher level of pretax book loss and the related increase in the foreign tax rate differential benefit.

### Net Income (Loss)

Net income for the three months ended September 30, 2017 was $43,371 or $0.02 profit per basic and diluted common share compared to net income for the three months ended September 30, 2016 of $0.1 million or $0.02 profit per basic and diluted common share. Net income for the nine months ended September 30, 2017 was $13,052 with no earnings per basic and diluted common share compared to net loss for the nine months ended September 30, 2016 of $0.1 million or $0.02 loss per basic and diluted common share.

### Liquidity and Capital Resources

We had total cash of $1.1 million consisting of unrestricted cash of $0.5 million and restricted cash of $0.6 million.

Net cash provided in operating activities decreased by $1.3 million to $0.6 million for the nine months ended September 30, 2017 compared to $1.9 million for the nine months ended September 30, 2016. Increases in our overall accounts receivable and timing of account payable disbursements have negatively impacted cash flows, offset by positive cash flow impacts in inventory and customer deposits which are included in other accrued liabilities on the condensed consolidated balance sheets.

Net cash provided by investing activities was nearly zero for the nine months ended September 30, 2017, which was generated from the proceeds of the sale of the Augusta building (see Note 6), offset by lower property and equipment purchases to support the business.

We have satisfied our liquidity needs over the past several years with cash flows generated from operations and a bank operating line of credit. We have a credit agreement with Bank of America (BofA) which was entered into on June 15, 2017 and provides for a line of credit arrangement of $16.0 million that expires on June 15, 2022. The credit arrangement also has a $5.0 million real estate term note outstanding with a maturity date of June 15, 2022.

Both the line of credit and real estate term notes are subject to fluctuations in the LIBOR rates. The line of credit and real estate term notes with BofA contain certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures. The availability under our line is subject to borrowing base requirements, and advances are at the discretion of the lender. The line of credit is secured by substantially all of our assets.

On September 30, 2017, we had outstanding advances of $8.5 million under the line of credit and unused availability of $4.5 million supported by our borrowing base compared to $5.7 million available on December 31, 2016. We believe our financing arrangements and cash flows to be provided by operations will be sufficient to satisfy our future working capital needs. Our working capital was $20.9 million and $19.2 million as of September 30, 2017 and December 31, 2016, respectively.

The Bank of America credit agreement provides for, among other things, a fixed charge coverage ratio of not less than (i) 1.00 to 1.00 for the trailing four fiscal quarters most recently ended. As of September 30, 2017, we were in compliance with this covenant.

Cash conversion cycle:

|  | Three Months Ended September 30, 2017 | 2016 | Nine Months Ended September 30, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| Days in trade accounts receivable | 55 | 55 | 53 | 53 |
| Days in inventory | 79 | 77 | 77 | 76 |
| Days in accounts payable | (52) | (53) | (52) | (47) |
| Cash conversion cycle | 82 | 79 | 78 | 82 |

We calculate days in accounts receivable as accounts receivable for the respective quarter and year-to-date period divided by annualized sales for the respective quarter and year-to-date period by day. We calculate days in inventory and accounts payable as each balance sheet line item for the respective quarter and year-to-date period divided by annualized cost of sales for the respective quarter and year-to-date period by day. We calculate cash conversion cycle as the sum of days in receivable and inventory less days in accounts payable. Items which may cause the cash conversion cycle in a particular period to differ include, but are not limited to, changes in business mix, changes in payment terms and the timing of revenue recognition and inventory purchases within the period. Days in accounts payable for the three and nine months ended September 30, 2017 decreased by one day and increased five days compared to the three and nine months ended September 30, 2016, as a result of the timing of payments. Days in inventory for the three and nine months ended September 30, 2017 weakened by two days and one day, respectively compared to the three and nine months ended September 30, 2016. The days in accounts receivable remained consistent.

### Off-Balance Sheet Arrangements

We have not engaged in any off-balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.

### Critical Accounting Policies and Estimates

Our significant accounting policies and estimates are summarized in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2016. There have been no significant changes in these critical accounting policies since December 31, 2016. Some of our accounting policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial estimates. Such judgments are subject to an inherent degree of uncertainty. These judgments are based on our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources, as appropriate. Actual results could differ from these estimates.

### Forward-Looking Statements

Those statements in the foregoing report that are not historical facts are forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally will be accompanied by words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “possible,” “potential,” “predict,” “project,” or other similar words that convey the uncertainty of future events or outcomes. Although we believe these forward-looking statements are reasonable, they are based upon a number of assumptions concerning future conditions, any or all of which may ultimately prove to be inaccurate. Forward-looking statements involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from the forward-looking statements include, without limitation:

- Volatility in the marketplace which may affect market supply and demand for our products;
- Increased competition;
- Changes in the reliability and efficiency of operating facilities or those of third parties;
- Risks related to availability of labor;
- Increase in certain raw material costs such as copper;
- Commodity and energy cost instability;
- Risk of dependence on a customer that represents a significant portion of our sales;
- Possible customer cancellations of orders, impact of financial difficulty of customers and other factors that could cause losses relating to customer orders;
- General economic, financial and business conditions that could affect our financial condition and results of operations; and
- Availability of raw material components.

The factors identified above are believed to be important factors (but not necessarily all of the important factors) that could cause actual results to differ materially from those expressed in any forward-looking statement made by us. Unpredictable or unknown factors not discussed herein could also have material adverse effects on forward-looking statements. All forward-looking statements included in this Form 10-Q are expressly qualified in their entirety by the forgoing cautionary statements. We undertake no obligations to update publicly any forward-looking statement (or its associated cautionary language) whether as a result of new information or future events.

Please refer to forward-looking statements and risks as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

## Controls and procedures

As filed, 1,458 characters.

### Evaluation of Disclosure Controls and Procedures

In accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q, our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). These controls and procedures are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulated and communicated to management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of these disclosure controls and procedures as of the date of the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective.

### Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Filed Nov 8, 2017.
Source: SEC EDGAR, the filing index for accession 0001104659-17-066996. Last ingested by Listed: Nov 12, 2026, 19:20 ET. No prices; not investment advice.
